1. Home
  2. Stocks
  3. Fredun Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Fredun Pharmaceuticals Share Price

    Small Cap
    ₹779.00
    + 2.25 (0.29%)
    19 September, 2024 13:37 BSE: 539730 NSE: FREDUN ISIN: INE194R01017

    Start SIP in Fredun Pharmaceuticals

    Start SIP

    Fredun Pharmaceuticals Performance

    Day Range

    • Low 0
    • High 0
    ₹ 779

    52 Week Range

    • Low 0
    • High 0
    ₹ 779
    • Open Price0
    • Previous Close0
    • Volume

    Fredun Pharmaceuticals Chart

    • Over 1 Month -2.61%
    • Over 3 Month -15.34%
    • Over 6 Month + 6.93%
    • Over 1 Year -14.47%

    Fredun Pharmaceuticals Key Statistics

    Fredun Pharmaceuticals Investment Rating

    • Master Rating:

    • Fredun Pharmaceuticals has an operating revenue of Rs. 363.70 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 6% is okay, ROE of 12% is good. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 11 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Fredun Pharmaceuticals Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 7811787816180
    Operating Expenses Qtr Cr 6810776725468
    Operating Profit Qtr Cr 911109712
    Depreciation Qtr Cr 111111
    Interest Qtr Cr 444334
    Tax Qtr Cr 112224
    Net Profit Qtr Cr 454424
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 349276
    Operating Expenses Annual Cr 310247
    Operating Profit Annual in Cr 3928
    Depreciation Cr 43
    Interest Annual Cr 149
    Tax Annual Cr 67
    Net Profit Annual Cr 1611
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 0-14
    Cash from Investing Activity Annual Cr -8-9
    Cash from Financing Annual Activity Cr 625
    Net Cash Flow Annual Cr -21
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 12196
    Fixed Assets Annual Cr 4739
    Total Non Current Assets Annual Cr 5041
    Total Current Assets Annual Cr 257216
    Total Assets Annual Cr 308257
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 258213
    ROE Annual % 1311
    ROCE Annual % 2618
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1111
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr
    Operating Expenses Qtr Cr
    Operating Profit Qtr Cr
    Depreciation Qtr Cr
    Interest Qtr Cr
    Tax Qtr Cr
    Net Profit Qtr Cr
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr
    Operating Expenses Annual Cr
    Operating Profit Annual in Cr
    Depreciation Cr
    Interest Annual Cr
    Tax Annual Cr
    Net Profit Annual Cr
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr
    Cash from Investing Activity Annual Cr
    Cash from Financing Annual Activity Cr
    Net Cash Flow Annual Cr
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr
    Fixed Assets Annual Cr
    Total Non Current Assets Annual Cr
    Total Current Assets Annual Cr
    Total Assets Annual Cr
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs
    ROE Annual %
    ROCE Annual %
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin %
    Invest in Fredun Pharmaceuticals

    Fredun Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹779.00
    + 2.25 (0.29%)
    pointer
    • Bullish Moving Average
    • ___
    • 0
    • Bearish Moving Average
    • ___
    • 16
    • 20 Day
    • ₹791.38
    • 50 Day
    • ₹808.52
    • 100 Day
    • ₹822.74
    • 200 Day
    • ₹840.94
    • 20 Day
    • ₹790.33
    • 50 Day
    • ₹814.41
    • 100 Day
    • ₹838.42
    • 200 Day
    • ₹836.71

    Fredun Pharmaceuticals Resistance and Support

    PIVOT
    ₹779.85
    Resistance
    First Resistance 788.70
    Second Resistance 800.65
    Third Resistance 809.50
    RSI 42.83
    MFI 36.16
    MACD Single Line -9.30
    MACD -8.13
    Support
    First Support 767.90
    Second Support 759.05
    Third Supoort 747.10

    Fredun Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 4,069 328,612 80.76
    Week 3,658 280,014 76.54
    1 Month 6,705 511,383 76.27
    6 Month 9,012 681,224 75.59

    Fredun Pharmaceuticals Result Highlights

    Fredun Pharmaceuticals Synopsis

    BSE-Medical-Diversified

    Fredun Pharma is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 349.07 Cr. and Equity Capital is Rs. 4.70 Cr. for the Year ended 31/03/2024. Fredun Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 08/06/1987 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1987PLC043662 and registration number is 043662.
    Market Cap 362
    Sales 364
    Shares in Float 0.24
    No of funds 1
    Yield 0.09
    Book Value 3
    U/D Vol ratio 1
    LTDebt / Equity 4
    Alpha -0.14
    Beta 1.11

    Fredun Pharmaceuticals Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23
    Promoters 49.17%49.17%49.16%
    Financial Institutions/ Banks 1.6%1.6%1.6%
    Individual Investors 43.88%44.02%43.67%
    Others 5.35%5.21%5.57%

    Fredun Pharmaceuticals Management

    Name Designation
    Dr.(Mrs.) Daulat N Medhora Chairman & Jt. M. D
    Mr. Fredun Medhora Managing Director & CFO
    Mr. Nariman Medhora Non Executive Director
    Dr. Aspi Raimalwala Ind. Non-Executive Director
    Dr. Rohinton Kanga Ind. Non-Executive Director

    Fredun Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Fredun Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-07-29 Quarterly Results
    2024-05-07 Audited Results & Final Dividend
    2024-02-14 Quarterly Results
    2023-12-16 Others Rs.0.00 alia, to consider a proposal for fund raising up to Rs.120 crores by way of further public offer, rights issue, debt issue, preferential issue or any other method.
    2023-11-08 Quarterly Results
    Date Purpose Remarks
    2023-09-22 FINAL Rs.0.70 per share(7%)Final Dividend

    Fredun Pharmaceuticals MF Shareholding

    Name Amount(cr)

    Fredun Pharmaceuticals FAQs

    What is Share Price of Fredun Pharmaceuticals ?

    Fredun Pharmaceuticals share price is ₹779 As on 19 September, 2024 | 13:23

    What is the Market Cap of Fredun Pharmaceuticals ?

    The Market Cap of Fredun Pharmaceuticals is ₹363.3 Cr As on 19 September, 2024 | 13:23

    What is the P/E ratio of Fredun Pharmaceuticals ?

    The P/E ratio of Fredun Pharmaceuticals is 20.9 As on 19 September, 2024 | 13:23

    What is the PB ratio of Fredun Pharmaceuticals ?

    The PB ratio of Fredun Pharmaceuticals is 3 As on 19 September, 2024 | 13:23

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.